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ing agentsAbstract Two simple, accurate, novel, safe and precise methods were developed for the simulta-
neous estimation of poorly water-soluble drugs Metronidazole (MTR) and Furazolidone (FZ) in
a tablet dosage form using 2 M sodium acetate and 8 M urea solution (50:50%V/V) as a mixed
hydrotropic solution. MTR and FZ show maximum absorbances at 319 and 364 nm, respectively.
Sodium acetate and urea solution did not show any absorbance above 240 nm and thus no interfer-
ence in the estimation of drugs was seen. MTR and FZ follow Beer’s law in the concentration range
of 10–50 lg/ml and 5–25 lg/ml (r2 = 0.9992 and 0.9996). Method-A employs the simultaneous
equation method using 319 and 364 nm as two analytical wavelengths, method-B employs the
absorption ratio method, which uses 339.2 and 364 nm as two analytical wavelengths for estimation
of MTR and FZ. The mean percent label claims of tablet dosage were found to be 98.715 ± 1.012
and 98.74 ± 0.912 in method A, 98.99 ± 0.872 and 97.89 ± 0.903 in method B for MTR and FZ,
respectively. The developed methods were validated according to ICH guidelines and values of
accuracy, precision and other statistical analysis were found to be in good accordance with the pre-
scribed values therefore both methods can be used for routine monitoring of MTR and FZ in indus-
try in the assay of bulk drug and tablets.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Metronidazole (MTR) chemically 2-(2-methyl-5-nitro-1H-imi-
dazol-1-yl) ethanol (Fig. 1), is a nitroimidazole used to treat





Figure 1 Chemical Structure of Metronidazole.
152 R. Jain et al.obic bacteria and treponemal infections. It is also used to treat
Crohn’s disease (Sweetman, 1999; Oneil et al., 2001). Furazol-
idone (FZ) chemically 3-(5-nitrofurfurylideneamino)-2-oxazo-
lidinone (Fig. 2), is synthetic antimicrobial nitrofurans,
which acts in a broad antibacterial spectrum covering the
majority of gastrointestinal tract pathogens including Esche-
richia coli, staphylococci, Salmonella, Shigella, Proteus, Aero-
bacter aerogenes, Vibrio cholerae and Giardia lamblia
(Sweetman, 1999; Oneil et al., 2001).
Metronidazole is ofﬁcial in IP (Indian Pharmacopoeia,
2010), BP (British Pharmacopoeia, 2004), USP (The United
States Pharmacopoeia and The National Formulary, 2000).
The literature survey reveals that several analytical methods
viz. the UV method (Rehman et al., 2005; Adegoke and
Umoh, 2009), HPLC (Mustapha et al., 2006; Cox et al.,
2009) and voltammetry (Bartlett et al., 2005) method have
been reported for quantitative estimation of MTR. Quantita-
tion of metronidazole and spiramycin by LC–MS/MS (Sagan
et al., 2005), HPLC with UV detection method (Maher
et al., 2008) and potentiometric (Khattab et al., 2011) method
has been reported.
Furazolidone is ofﬁcial in IP (Indian Pharmacopoeia, 2010)
and USP (The United States Pharmacopoeia and The Na-
tional Formulary, 2000). The literature survey reveals that var-
ious analytical methods have been developed such as HPLC
(Cieri, 1979), HPTLC (Shirke et al., 1994), UV–Visible Spec-
trophotometry (Ravisankar et al., 1998), liquid chromatogra-
phy with electrochemical detection (Germain et al., 1990),
turbidimetric method (Gang and Shaikh, 1972) for the estima-
tion of FZ in biological ﬂuids and in pharmaceutical formula-
tions. Some reports are available for the estimation of MTR
and FZ in a tablet dosage form by UV methods (Lopez-de-
Alba et al., 1997; Basu and Mahalanabis, 1991; Kale et al.,
2012; Chemate et al., 2012).
Hydrotropic solubilization is the phenomenon by which
aqueous solubility of poorly water soluble drugs and insoluble
drugs increases. Various techniques have been employed to en-
hance the aqueous solubility and hydrotropy is one of them.
Sodium salicylate, sodium benzoate, urea, nicotinamide, so-









Figure 2 Chemical Structure of Furazolidone.ples of hydrotropic agents utilized to increase the water
solubility of the drug. Maheshwari (2005, 2006) and (Jain
et al. (2010a,b,c,d) have analyzed various poorly water-soluble
drugs using hydrotropic solubilization phenomenon viz. keto-
profen, salicylic acid, frusemide, torsemide, hydrochlorothia-
zide, pramipexole and amlodipine besylate. Various organic
solvents such as methanol, chloroform, dimethyl formamide
and acetonitrile have been employed for solubilization of
poorly water-soluble drugs to carry out spectrophotometric
analysis. Drawbacks of organic solvents include their higher
cost, toxicity and pollution. Hydrotropic solution may be a
proper choice to preclude the use of organic solvents.
Therefore, it was thought worthwhile to employ this mixed
hydrotropic solution to extract out the drug from ﬁne powder
of tablets to carry out spectrophotometric estimation. There
are no reports yet for the determination of this combination
by proposed methods. The present work emphasizes on the
quantitative estimation of MTR and FZ in their combined
dosage form by UV Spectroscopic methods.2. Experimental procedure
2.1. Materials and methods
Pure sample of MTR and FZ was obtained as a gift sample
from Swan pharmaceutical, Indore and GSK Ltd. Mumbai,
respectively. Sodium acetate and urea were obtained from
Merck Chemical Division, Mumbai. Reverse osmosis water
was used throughout the study. A Shimadzu UV/VIS 1700
spectrophotometer with 1 cm matched quartz cells was used
for the estimation.2.2. Preliminary solubility studies of drugs
Solubility of both drugswas determined at 25 ± 1 C.An excess
amount of drug was added to two screw capped 25 ml of volu-
metric ﬂasks containing different aqueous systems viz. distilled
water and different combination of hydrotropic agent. The vol-
umetric ﬂaskswere shakenmechanically for 12 h at 25 ± 1 C in
a mechanical shaker. These solutions were allowed to equili-
brate for next 24 h. and then centrifuged for 5 min at
2000 rpm. The supernatant liquid was taken for appropriate
dilution after ﬁltering through Whatman ﬁlter paper #41 and
analyzed spectrophotometrically against water as blank. After
analysis, it was found that the enhancement in the solubility of
MTRandFZwas found to bemore than 36 and 28 folds, respec-
tively in a mixture of 2 M sodium acetate and 8 M urea solution
(1:1) as compared to solubility studies in other solvents.2.3. Selection of hydrotropic agent
MTR and FZ were scanned in hydrotropic agent in the spec-
trum mode over the UV range 200–400 and a mixture of
2 M sodium acetate and 8 M urea (50:50% V/V) solution
was found to be most appropriate because:
n MTR and FZ are soluble in it (36 and 28 fold enhance-
ment of solubility)
n MTR and FZ are stable in hydrotropic agent.
Table 1 Optical characteristics and linearity data of MTR
and FZ.
Sr. No. Parameters MTR FZ
1 Working k 319 nm 364 nm
2 Beer’s law limit (lg/ml) 10–50 5–25
3 Correlation coeﬃcient (r2)* 0.9992 0.9996
4 Slope (m)* 0.0277 0.0600
5 Intercept (c)* 0.0229 0.0115
6 LOD (lg/ml) 0.323 0.443
7 LOQ (lg/ml) 0.082 0.743
* Average of ﬁve determinations.
UV spectrophotometer methods for quantitative estimation of MTR and FZ 153n MTR and FZ, both exhibit good spectral characteris-
tics in it.
n Sodium acetate and urea solution have no interference
with the kmax of MTR and FZ, 319 and 364 nm, respec-
tively (Fig. 3).
2.4. Establishment of stability proﬁle
Stability of MTR and FZ was observed by dissolving in a mix-
ture of 2 M sodium acetate and 8 M urea (50:50% V/V) solu-
tion used as hydrotropic agent. Solution of MTR and FZ was
scanned under time scan for 30 min. Spectra of the drug under
time scan shows that drug is stable in hydrotropic solution.
2.5. Linearity range and calibration graph
2.5.1. Preparation of standard stock solutions of MTR and FZ
Standard stock solutions of 1000 lg/ml were prepared by dis-
solving separately 100 mg of each drug in mixed hydrotropic
solution and the ﬂask was sonicated for about 10 min to solu-
bilize the drug (Stock-A).
2.5.2. Preparation of working standard solution for calibration
curve
The standard solution (1000 lg/ml) was further diluted in dif-
ferent dilutions and prepared ranging from 10–50 lg/ml for
MTR and 5–25 lg/ml for FZ. The calibration curve was plot-
ted between concentrations and absorbances. Linearity data
and result of their optical characteristics are shown in Table 1).
2.6. Study of overlay spectra of drugs and selection of method
The spectra exhibit major absorbance maxima at 319 nm and
364 nm for MTR and FZ, respectively and isosbestic point
at 339.2 nm Fig. 3. Due to difference in absorbance maxima
and having no interference with each other both drugs can
be simultaneously estimated by the simultaneous equation
method (Method A) and the Q-analysis method (Method B).
2.6.1. Vierordt’s simultaneous equation method (Method A)
The wavelength 319 nm (kmax of MTR) and 364 nm (kmax of
FZ) was selected. The absorbencies of MTR and FZ were mea-
sured at 319 nm and 364 nm. This method of analysis is based
on the absorption of drugs X and Y at the wavelength maxima
of the other. The quantiﬁcation analysis of MTR and FZ in a
binary mixture was performed by using Eqs. (1) and (2). Where
CX and CY are the concentrations of MTR and FZ, respec-Figure 3 Overlay Spectra of MTR 50 lg/ml and FZ 25 lg/ml.tively in the diluted sample, ax1 and ax2 are absorptivities of
MTR at k1 and k2, ay1 and ay2 are absorptivities of FZ at
k1 and k2, respectively (Table 2)). A1 and A2 are the absor-
bances of samples at the 319 and 364 nm, respectively (Beckett
et al., 2002).
CX ¼ A2ay1 A1ay2=ax2ay1  ax1ay2 ð1Þ
CY ¼ A1ax2 A2ax1=ax2ay1  ax1ay2 ð2Þ2.6.2. Q-analysis method (Method B)
In this method absorbances of both the drugs were calculated
at two selected wavelengths; among which k1 is the wavelength
of isoabsorptive point of both drugs and k2 is the kmax of either
drug among both drugs. From the overlain spectra wavelength
339.2 nm (isoabsorption point) and 364 (kmax of FZ) were se-
lected for the study. The absorbencies at 339.2 nm and 364 nm
for MTR were obtained and similarly for FZ absorbencies are
measured at 339.2 nm and 364 nm. The concentrations of the
individual components were calculated by using the following
equations;
CX ¼ Qm Qy=Qx Qy A1=ax1 ð3Þ
CY ¼ Qm Qy=Qy Qx A1=ax1 ð4Þ
where Qm = A2/A1, A1 is absorbance of sample at isoabsorp-
tive point, A2 is absorbance of sample at kmax of one of the two
components. ax1 and ax2 represent absorptivities of MTR at k1
and k2 and ay1 and ay2 denote absorptivities of FZ at k1 and
k2, respectively (Table 2); CX and CY are the concentrations
of MTR and FZ, respectively (Beckett et al., 2002; Pernarow-
ski et al., 1960)
3. Analysis of tablet formulation
Twenty marketed tablets of MTR and FZ, Metrofur (Western
Remedies) were weighed and ground to a ﬁne powder; amount
equal to 200 mg of MTR was taken in a 10 ml volumetric ﬂask.
The FZ present in this amount of tablet powder was 100 mg.
Then 80 ml of sodium acetate and urea solution was added
and the ﬂask was sonicated for about 10 min to solubilize
the drug present in tablet powder and the volume was made
up to the mark with hydrotropic solution. After sonication ﬁl-
tration was done through Whatman ﬁlter paper No. 41. Fil-
trate was collected and further diluted with RO water to get
the ﬁnal concentrations of both drugs in the working range.
The absorbances of ﬁnal dilutions were observed at selected
Table 2 Absorptivities of MTR (x) and FZ (y) at k1 and k2.
Drug Method-I Method-II
319 nm (k1) 364 nm (k2) 339.2 nm (k1) 364 nm (k2)
MTR ax1 0.0249 ax2 0.0054 ax1 0.0180 ax2 0.0054
FZ ay1 0.0239 ay2 0.0614 ay1 0.0435 ay2 0.0614
QX 0.3000 QY 1.4115
N= 5
154 R. Jain et al.wavelengths and the concentrations were obtained from the
simultaneous equation method and the absorbance ratio meth-
od. The result of statistical evaluation of tablet analysis is re-
ported in Table 3.
4. Validation of method
The developed methods for simultaneous estimation of EPS
and HCZ were validated as per ICH guidelines (Linearity,
Accuracy, Precision and Robustness) (ICH, 2005).
4.1. Linearity
Linearity of MTR and FZ was established by response ratios
of drugs. Response ratio of both drugs was calculated byTable 5 Results of validation (Mean ± SD).
Parameter Method – A
Precision (Mean ± SD)* MTR % RSD FZ
Repeatability 98.12 ± 1.09 1.111 99.55 ± 0.93
Day to day 98.35 ± 0.85 0.864 99.46 ± 0.65
Analyst to analyst 98.24 ± 0.83 0.845 98.73 ± 0.93
Reproducibility 97.69 ± 0.73 0.747 98.24 ± 1.12
Robustness* (Ratio) 98.38 ± 0.25 0.254 98.19 ± 1.02
(Temperature) 97.68 ± 0.93 0.952 98.55 ± 0.28
(Concentration) 98.78 ± 0.27 0.273 98.69 ± 0.85
* Average of ﬁve determinations.
Table 3 Results and statistical parameters for tablet analysis: Metr
S. No. Drug Label claim Amount found
Method A MTR 200 197.43
FZ 100 98.74
Method B MTR 200 197.98
FZ 100 97.89
* Average of ﬁve determinations.
Table 4 Results of Recovery Studies on Marketed Formulations.
Recovery level% % Recovery (Mean ± SD)*
Method A
MTR FZ
80 98.39 ± 1.023 98.36 ±
100 97.45 ± 0.903 98.42 ±
120 98.64 ± 0.172 98.54 ±
Mean 98.16 ± 0.699 98.44 ±
* Average of ﬁve determination.dividing the absorbance with respective concentration and
then a graph was plotted between concentration and response
ratio.4.2. Limit of detection (LOD) and limit of quantiﬁcation
(LOQ)
The LOD and LOQ of MTR and FZ were determined by using
standard deviation of the response and slope approach as de-
ﬁned in International Conference on Harmonization (ICH)
guidelines. The limit of detection (LOD) and limit of
quantiﬁcation (LOQ) for MTR and FZ were found to be
0.323 lg/ml, 0.082 lg/ml and 0.443 lg/ml, 0.743 lg/ml, respec-
tively (Table 1) indicating that the proposed UV method is
highly sensitive.Method – B
% RSD MTR % RSD FZ % RSD
0.934 98.09 ± 0.32 0.326 98.62 ± 0.94 0.953
0.654 98.86 ± 0.47 0.475 98.43 ± 0.88 0.894
0.942 98.74 ± 0.61 0.618 98.41 ± 0.39 0.396
1.140 98.66 ± 0.46 0.466 98.34 ± 0.22 0.224
1.039 98.84 ± 1.04 1.052 99.51 ± 0.81 0.814
0.284 98.85 ± 0.61 0.617 97.86 ± 0.76 0.776
0.861 98.78 ± 0.57 0.577 98.79 ± 0.46 0.465
ofur (MTR-200/FZ-100).
Recovery%* S.D.* %COV* STD. error*
98.715 1.012 1.025 0.187
98.74 0.912 0.924 0.169
98.99 0.872 0.881 0.161
97.89 0.903 0.922 0.169
Method B
MTR FZ
0.868 98.44 ± 0.869 98.67 ± 0.721
0.475 97.93 ± 0.722 98.40 ± 0.172
0.673 97.85 ± 0.343 97.74 ± 0.451
0.672 98.07 ± 0.644 98.27 ± 0.448
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The accuracy of the proposed methods was assessed by recov-
ery studies at three different levels i.e., 80%, 100% and 120%.
The recovery studies were carried out by adding a known
amount of standard solution of MTR and FZ to preanalyzed
tablet solutions. The resulting solutions were then re-analyzed
by proposed methods. Total amount of drug found and per-
centage recovery were calculated. Results of recovery studies
are reported in Table 4.
4.4. Precision
Precision of the methods was studied at three levels as repeat-
ability, intermediate precision (Day to Day and analyst to ana-
lyst) and reproducibility (Table 5).
4.5. Robustness
For the robustness of the analytical method we changed the
temperature 25 ± 5 C, centrifugation time 10 min and the ra-
tio of hydrotropic solution. Instead the 50:50 ratios of sodium
acetate and urea and 60:40 sodium acetate and urea were used
as solvent (Table 5).
5. Results and discussions
Based on the solubility and stability and spectral characteris-
tics of the drugs, 2 M sodium acetate and 8 M urea solution
(50:50% W/V) were used as a mixed hydrotropic solution. It
was found that solubility enhancement of MTR and FZ was
more than 36 and 28-fold, respectively in mixed hydrotropic
solution as compared with distilled water. MTR and FZ
show maximum absorbances at 319 and 364 nm, respectively.
Sodium acetate and urea solution did not show any absor-
bance above 240 nm and thus no interference in the estima-
tion of drugs was seen. MTR and FZ follow Beer’s law in
the concentration range of 10–50 lg/ml and 5–25 lg/ml
(r2 = 0.9992 and 0.9996). Method-A employs the simulta-
neous equation method using 319 and 364 nm as two analyt-
ical wavelengths, method-B employs the absorption ratio
method, which uses 339.2 and 364 nm as two analytical wave-
lengths for estimation of MTR and FZ. The optimized meth-
ods showed good reproducibility and mean recovery with
98.16 ± 0.699 and 98.44 ± 0.672 in method A and
98.07 ± 0.644 and 98.27 ± 0.448 in method B for MTR
and FZ, respectively. The mean percent label claims of tablet
dosage were found to be 98.715 ± 1.012 and 98.74 ± 0.912
in method A, 98.99 ± 0.872 and 97.89 ± 0.903 in method
B for MTR and FZ, respectively. The standard deviation,
coefﬁcient of variance and standard error were obtained for
MTR and FZ were satisfactorily low. Result of precision at
different levels was found to be within acceptable limits
(RSD < 2).
6. Conclusion
There was no interference of 2 M sodium acetate and 8 M urea
solution (50:50% W/V) in the estimation and hence the two
UV spectrophotometric methods were found to be simple,accurate, economic and rapid for simultaneous estimation of
MTR and FZ in bulk and tablet dosage forms. The proposed
method can be successfully employed for the routine analysis
of MTR and FZ containing dosage forms.
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